A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Patients with Immunoglobulin A Nephropathy (IgAN)
November 5, 2022 | American Society of Nephrology (ASN) Kidney Week